FindTrial
Sign In

A study to find out if giving Simethicone (an anti-foaming medicine) to adults before colonoscopy helps get clearer views of the large intestine mucosa during procedure

Visibility Improvement with Simethicone and Triple Sulfate Agent (OSS) for Colonoscopy: A Double-Blind, Placebo-Controlled Randomized Trial - The VISTA trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092832
Enrollment
90
Registered
2025-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified

Interventions

Intervention1: Simethicone: Simethicone is an anti-foaming agent. 600mg (15ml) simethicone will be added to oral sulfate solution during colonoscopy preparation. Control Intervention1: Placebo: 15ml d

Sponsors

Delvin Formulations Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults between 18 to 70 years of age scheduled for colonoscopy at the gastroenterological unit 2. No clinical evidence of partial or complete colonic obstruction 3. Treatment na ve or follow up patients except patients who undergone right or left hemicolectomy 4. Written informed consent provided.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1. Bowel Preparation Quality (BBPS Score) 2. Mucosal Visibility and Defoaming (CEBuS Score)Timepoint: During the procedure—

Secondary

MeasureTime frame
1. Colonoscopy Procedure Duration 2. Adverse eventsTimepoint: During the procedure—

Countries

India

Contacts

Public ContactDr L Sujatha

Cancer Institute (WIA), Adyar

drsujatha@ymail.com9500037675

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026